Christina Piperi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3688963/publications.pdf

Version: 2024-02-01

209 papers 7,442 citations

47006 47 h-index 71 g-index

209 all docs

209 docs citations

times ranked

209

10091 citing authors

#	Article	IF	CITATIONS
1	Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas. Current Neuropharmacology, 2023, 21, 457-470.	2.9	10
2	Emerging roles for the YAP/TAZ transcriptional regulators in brain tumour pathology and targeting options. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	10
3	Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson's Disease Pathogenesis: A Narrative Review. Brain Sciences, 2022, 12, 175.	2.3	31
4	Central Role of C2H2-Type Zinc Finger-Containing Genes in Pediatric Brain Tumors. Dna, 2022, 2, 1-21.	1.3	0
5	Pathogenic Molecular Mechanisms in Periodontitis and Peri-Implantitis: Role of Advanced Glycation End Products. Life, 2022, 12, 218.	2.4	14
6	Polycystinâ€1 and hydrostatic pressure are implicated in glioblastoma pathogenesis in vitro. Journal of Cellular and Molecular Medicine, 2022, 26, 1699-1709.	3.6	5
7	Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential. International Journal of Molecular Sciences, 2022, 23, 1693.	4.1	32
8	Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma. Cancers, 2022, 14, 1070.	3.7	5
9	Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer. International Journal of Oncology, 2022, 60, .	3.3	5
10	Polycystinâ€1 regulates cell proliferation and migration through AKT/mTORC2 pathway in a human craniosynostosis cell model. Journal of Cellular and Molecular Medicine, 2022, 26, 2428-2437.	3.6	7
11	Transcription Factors with Targeting Potential in Gliomas. International Journal of Molecular Sciences, 2022, 23, 3720.	4.1	11
12	Ag/Au Bimetallic Nanoparticles Trigger Different Cell Death Pathways and Affect Damage Associated Molecular Pattern Release in Human Cell Lines. Cancers, 2022, 14, 1546.	3.7	18
13	Crosstalk of Epigenetic and Metabolic Signaling Underpinning Glioblastoma Pathogenesis. Cancers, 2022, 14, 2655.	3.7	6
14	Epigenetic mechanisms regulate sex-specific bias in disease manifestations. Journal of Molecular Medicine, 2022, 100, 1111-1123.	3.9	15
15	Targeting post-translational histone modifying enzymes in glioblastoma. , 2021, 220, 107721.		58
16	Epigenetic mechanisms regulating COVID-19 infection. Epigenetics, 2021, 16, 263-270.	2.7	103
17	Emerging role of S100B protein implication in Parkinson's disease pathogenesis. Cellular and Molecular Life Sciences, 2021, 78, 1445-1453.	5.4	27
18	Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases. Progress in Neurobiology, 2021, 200, 101968.	5.7	18

#	Article	IF	CITATIONS
19	Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?. Molecular Neurobiology, 2021, 58, 1372-1391.	4.0	20
20	Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential. Cancer Research, 2021, 81, 525-534.	0.9	48
21	Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. European Endocrinology, 2021, 1, 37.	1.5	0
22	Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. European Endocrinology, 2021, 17, 37.	1.5	7
23	Neuroprotective potential of cinnamon and its metabolites in Parkinson's disease: Mechanistic insights, limitations, and novel therapeutic opportunities. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22720.	3.0	26
24	Bivalent Genes Targeting of Glioma Heterogeneity and Plasticity. International Journal of Molecular Sciences, 2021, 22, 540.	4.1	7
25	Role of Liver Growth Factor (LGF) in Parkinson's Disease: Molecular Insights and Therapeutic Opportunities. Molecular Neurobiology, 2021, 58, 3031-3042.	4.0	3
26	Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis. International Journal of Molecular Sciences, 2021, 22, 2778.	4.1	19
27	Polycystinâ€1 modulates RUNX2 activation and <i>osteocalcin</i> gene expression via ERK signalling in a human craniosynostosis cell model. Journal of Cellular and Molecular Medicine, 2021, 25, 3216-3225.	3.6	8
28	Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. PLoS ONE, 2021, 16, e0248298.	2.5	14
29	Impact of Epigenetic Alterations in the Development of Oral Diseases. Current Medicinal Chemistry, 2021, 28, 1091-1103.	2.4	19
30	Novel therapeutic approaches for cutaneous T cell lymphomas. Expert Review of Clinical Immunology, 2021, 17, 629-641.	3.0	6
31	Central Regulatory Role of Cytokines in Periodontitis and Targeting Options. Current Medicinal Chemistry, 2021, 28, 3032-3058.	2.4	43
32	Impact of the apelin/APJ axis in the pathogenesis of Parkinson's disease with therapeutic potential. Journal of Neuroscience Research, 2021, 99, 2117-2133.	2.9	8
33	Histone Mark Profiling in Pediatric Astrocytomas Reveals Prognostic Significance of H3K9 Trimethylation and Histone Methyltransferase SUV39H1. Neurotherapeutics, 2021, 18, 2073-2090.	4.4	5
34	APOE Genotype and Alzheimer's Disease: The Influence of Lifestyle and Environmental Factors. ACS Chemical Neuroscience, 2021, 12, 2749-2764.	3.5	37
35	Low ILâ€23 levels in peripheral blood and bone marrow at diagnosis of acute leukemia in children increased with the elimination of leukemic burden. Journal of Cellular and Molecular Medicine, 2021, 25, 7426-7435.	3.6	2
36	Pivotal role of Transient Receptor Potential Channels in oral physiology. Current Medicinal Chemistry, 2021, 28, .	2.4	1

#	Article	IF	CITATIONS
37	Structure, Activity and Function of the SETDB1 Protein Methyltransferase. Life, 2021, 11, 817.	2.4	17
38	Structure, Activity and Function of the MLL2 (KMT2B) Protein Lysine Methyltransferase. Life, 2021, 11, 823.	2.4	10
39	Recent Developments in Diagnosis of Epilepsy: Scope of MicroRNA and Technological Advancements. Biology, 2021, 10, 1097.	2.8	16
40	Neuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders. Molecules, 2021, 26, 6456.	3.8	26
41	Dissecting the Role of Circular RNAs in Sarcomas with Emphasis on Osteosarcomas. Biomedicines, 2021, 9, 1642.	3.2	4
42	Neuroprotective potential of cinnamon and its metabolites in Parkinson's disease: Mechanistic insights, limitations, and novel therapeutic opportunities. Journal of Biochemical and Molecular Toxicology, 2021, , e22711.	3.0	2
43	Insights in the immunobiology of glioblastoma. Journal of Molecular Medicine, 2020, 98, 1-10.	3.9	46
44	Regulation of matrix metalloproteinase-1 by Filifactor alocis in human gingival and monocytic cells. Clinical Oral Investigations, 2020, 24, 1987-1995.	3.0	8
45	Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk. Pharmacological Research, 2020, 152, 104593.	7.1	53
46	Neuroprotective potential of chrysin in Parkinson's disease: Molecular mechanisms and clinical implications. Neurochemistry International, 2020, 132, 104612.	3.8	60
47	Critical role of HOX transcript antisense intergenic RNA (HOTAIR) in gliomas. Journal of Molecular Medicine, 2020, 98, 1525-1546.	3.9	13
48	Cutaneous T-cell lymphoma: aetiopathogenesis and current diagnostic and therapeutic developments. European Journal of Dermatology, 2020, 30, 85-102.	0.6	2
49	Arylsulfatase A (ASA) in Parkinson's Disease: From Pathogenesis to Biomarker Potential. Brain Sciences, 2020, 10, 713.	2.3	10
50	Role of Innate Immune Receptor TLR4 and its endogenous ligands in epileptogenesis. Pharmacological Research, 2020, 160, 105172.	7.1	26
51	Revisiting the Impact of Neurodegenerative Proteins in Epilepsy: Focus on Alpha-Synuclein, Beta-Amyloid, and Tau. Biology, 2020, 9, 122.	2.8	14
52	Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma. Cancer Letters, 2020, 489, 135-143.	7.2	18
53	Flotillin: A Promising Biomarker for Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 20.	2.5	19
54	HMGB1-Mediated Neuroinflammatory Responses in Brain Injuries: Potential Mechanisms and Therapeutic Opportunities. International Journal of Molecular Sciences, 2020, 21, 4609.	4.1	56

#	Article	IF	CITATIONS
55	Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington's disease. Journal of Molecular Medicine, 2020, 98, 325-334.	3.9	11
56	Unraveling the Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Myasthenia Gravis. ACS Chemical Neuroscience, 2020, 11, 663-673.	3.5	9
57	Potential Neuroprotective Effect of the HMGB1 Inhibitor Glycyrrhizin in Neurological Disorders. ACS Chemical Neuroscience, 2020, 11, 485-500.	3.5	49
58	Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson's Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology. Biology, 2020, 9, 86.	2.8	19
59	Implication of HMGB1 signaling pathways in Amyotrophic lateral sclerosis (ALS): From molecular mechanisms to pre-clinical results. Pharmacological Research, 2020, 156, 104792.	7.1	17
60	Targeting of endoplasmic reticulum (ER) stress in gliomas. Pharmacological Research, 2020, 157, 104823.	7.1	40
61	Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications. Pharmacological Research, 2020, 158, 104930.	7.1	39
62	From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod. Current Neuropharmacology, 2020, 18, 1126-1137.	2.9	15
63	Impact of HMGB1, RAGE, and TLR4 in Alzheimer's Disease (AD): From Risk Factors to Therapeutic Targeting. Cells, 2020, 9, 383.	4.1	146
64	Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential. NeuroMolecular Medicine, 2019, 21, 227-238.	3.4	28
65	Emerging Pathogenic and Prognostic Significance of Paired Box 3 (PAX3) Protein in Adult Gliomas. Translational Oncology, 2019, 12, 1357-1363.	3.7	4
66	High mobility group box 1 (HMGB1) protein in Multiple Sclerosis (MS): Mechanisms and therapeutic potential. Life Sciences, 2019, 238, 116924.	4.3	20
67	miR-124 and Parkinson's disease: A biomarker with therapeutic potential. Pharmacological Research, 2019, 150, 104515.	7.1	80
68	Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment. Cells, 2019, 8, 1398.	4.1	73
69	Tau Related Pathways as a Connecting Link between Epilepsy and Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 4199-4212.	3.5	27
70	Differential Expression of Apoptotic and Low-Grade Inflammatory Markers in Alzheimer Disease Compared to Diabetes Mellitus Type 1 and 2. journal of applied laboratory medicine, The, 2019, 3, 1003-1013.	1.3	4
71	Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling. European Journal of Pharmacology, 2019, 858, 172487.	3.5	134
72	Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients. International Journal of Molecular Sciences, 2019, 20, 937.	4.1	8

#	Article	IF	Citations
73	Impact of advanced glycation end products (AGEs) signaling in coronary artery disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 611-619.	3.8	71
74	Highâ€mobility group box 1 in Parkinson's disease: from pathogenesis to therapeutic approaches. Journal of Neurochemistry, 2018, 146, 211-218.	3.9	38
75	Acetyl Cholinesterase Inhibitors and Cell-Derived Peripheral Inflammatory Cytokines in Early Stages of Alzheimer's Disease. Journal of Clinical Psychopharmacology, 2018, 38, 138-143.	1.4	27
76	Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults. Journal of Infectious Diseases, 2018, 218, 26-34.	4.0	22
77	Advanced glycation end products interfere in luteinizing hormone and follicle stimulating hormone signaling in human granulosa KGN cells. Experimental Biology and Medicine, 2018, 243, 29-33.	2.4	22
78	Emerging role of plexins signaling in glioma progression and therapy. Cancer Letters, 2018, 414, 81-87.	7.2	31
79	Polycystin-1 downregulation induces ERK-dependent mTOR pathway activation in a cellular model of psoriasis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3468-3476.	3.8	13
80	Critical Role of IL-8 Targeting in Gliomas. Current Medicinal Chemistry, 2018, 25, 1954-1967.	2.4	20
81	Role of cathepsin S In periodontal wound healing–an in vitro study on human PDL cells. BMC Oral Health, 2018, 18, 60.	2.3	17
82	Impact of Aldehyde Dehydrogenase Activity on Gliomas. Trends in Pharmacological Sciences, 2018, 39, 605-609.	8.7	6
83	Chromatin remodeling defects in pediatric brain tumors. Annals of Translational Medicine, 2018, 6, 248-248.	1.7	9
84	Molecular mechanisms of mechanotransduction in psoriasis. Annals of Translational Medicine, 2018, 6, 245-245.	1.7	27
85	The role of transient receptor potential polycystin channels in bone diseases. Annals of Translational Medicine, 2018, 6, 246-246.	1.7	11
86	DPP-4 inhibitors: a promising therapeutic approach against Alzheimer's disease. Annals of Translational Medicine, 2018, 6, 255-255.	1.7	48
87	Molecular medicine in the translational research era. Annals of Translational Medicine, 2018, 6, 239-239.	1.7	1
88	Potential of glycative stress targeting for cancer prevention. Cancer Letters, 2017, 390, 153-159.	7.2	19
89	Dietary Advanced Glycation End-Products: Molecular mechanisms and Preventive Tools. Current Nutrition Reports, $2017, 6, 1-8$.	4.3	9
90	Continuous hydrostatic pressure induces differentiation phenomena in chondrocytes mediated by changes in polycystins, SOX9, and RUNX2. Journal of Orofacial Orthopedics, 2017, 78, 21-31.	1.3	15

#	Article	IF	CITATIONS
91	Association of skin autofluorescence with arterial properties: A closer look at AGE Reader and EndoPAT 2000 commercial devices. Experimental Gerontology, 2017, 98, 207-208.	2.8	2
92	Molecular Basis of Pediatric Brain Tumors. NeuroMolecular Medicine, 2017, 19, 256-270.	3.4	13
93	Recent Advances in Mechanobiology of Osteosarcoma. Journal of Cellular Biochemistry, 2017, 118, 232-236.	2.6	31
94	Mechanosensor polycystin-1 potentiates differentiation of human osteoblastic cells by upregulating Runx2 expression via induction of JAK2/STAT3 signaling axis. Cellular and Molecular Life Sciences, 2017, 74, 921-936.	5.4	41
95	Role of Cathepsin S in Periodontal Inflammation and Infection. Mediators of Inflammation, 2017, 2017, 1-10.	3.0	29
96	Systemic effects of AGEs in ER stress induction in vivo. Glycoconjugate Journal, 2016, 33, 537-544.	2.7	34
97	Plasma levels of lipoprotein (a) and apolipoprotein A1 in patients with probable Alzheimer's disease. Neurobiology of Aging, 2016, 39, S20.	3.1	0
98	Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. Scientific Reports, 2016, 6, 21252.	3.3	6
99	Additive effects of dietary glycotoxins and androgen excess on the kidney of a female rat model. Alexandria Journal of Medicine, 2016, 52, 159-168.	0.6	0
100	Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis. BMC Cancer, 2016, 16, 174.	2.6	55
101	Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression. Journal of Molecular Medicine, 2016, 94, 867-874.	3.9	35
102	XBP1: A Pivotal Transcriptional Regulator of Glucose and Lipid Metabolism. Trends in Endocrinology and Metabolism, 2016, 27, 119-122.	7.1	68
103	Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2–NF-κB and JNK–AP-1 signaling pathways. Cellular and Molecular Life Sciences, 2016, 73, 1685-1698.	5.4	70
104	Impact of Androgen and Dietary Advanced Glycation End Products on Female Rat Liver. Cellular Physiology and Biochemistry, 2015, 37, 1134-1146.	1.6	9
105	Elevated expression of mechanosensory polycystins in human carotid atherosclerotic plaques: association with p53 activation and disease severity. Scientific Reports, 2015, 5, 13461.	3.3	22
106	Emerging Role of Linker Histone Variant $H1x$ as a Biomarker with Prognostic Value in Astrocytic Gliomas. A Multivariate Analysis including Trimethylation of H3K9 and H4K20. PLoS ONE, 2015, 10, e0115101.	2.5	30
107	Dietary glycotoxins induce RAGE and VEGF up-regulation in the retina of normal rats. Experimental Eye Research, 2015, 137, 1-10.	2.6	13
108	Expression of vascular endothelial factor-A, gelatinases (MMP-2, MMP-9) and TIMP-1 in uterine leiomyomas. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1415-24.	2.3	14

#	Article	IF	CITATIONS
109	AGE/RAGE signalling regulation by miRNAs: Associations with diabetic complications and therapeutic potential. International Journal of Biochemistry and Cell Biology, 2015, 60, 197-201.	2.8	61
110	Discovery of Immunodominant B Cell Epitopes within Surface Pneumococcal Virulence Proteins in Pediatric Patients with Invasive Pneumococcal Disease. Journal of Biological Chemistry, 2015, 290, 27500-27510.	3.4	12
111	Mitochondrial emitted electromagnetic signals mediate retrograde signaling. Medical Hypotheses, 2015, 85, 810-818.	1.5	9
112	Pathophysiological mechanisms regulated by cytokines in gliomas. Cytokine, 2015, 71, 377-384.	3.2	36
113	Polycystinâ€1 and polycystinâ€2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. International Journal of Cancer, 2015, 136, 1515-1527.	5.1	41
114	Polycystins and mechanotransduction: From physiology to disease. World Journal of Experimental Medicine, 2015, 5, 200.	1.7	23
115	Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones, 2014, 13, 65-73.	1.9	79
116	The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones, 2014, 13, 488-97.	1.9	11
117	Highâ€frequency <i>p16</i> <scp>^{<i>INK</i>}</scp> ^{<i>4A</i>} promoter methylation is associated with histone methyltransferase <scp>SETDB</scp> 1 expression in sporadic cutaneous melanoma. Experimental Dermatology, 2014, 23, 332-338.	2.9	33
118	Antigen-Specific B-Cell Response to 13-Valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Â-Thalassemia Previously Immunized With 23-Valent Pneumococcal Polysaccharide Vaccine. Clinical Infectious Diseases, 2014, 59, 862-865.	5 . 8	26
119	The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. BMC Cancer, 2014, 14, 149.	2.6	18
120	Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention?. Clinical Chemistry and Laboratory Medicine, 2014, 52, 189-200.	2.3	29
121	Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 473-485.	2.8	46
122	Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation. NeuroMolecular Medicine, 2014, 16, 70-82.	3 . 4	78
123	Impact of diet-induced obesity in male mouse reproductive system: The role of advanced glycation end product–receptor for advanced glycation end product axis. Experimental Biology and Medicine, 2014, 239, 937-947.	2.4	7
124	A new model for mitochondrial membrane potential production and storage. Medical Hypotheses, 2014, 83, 175-181.	1.5	67
125	Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Progress in Retinal and Eye Research, 2014, 42, 85-102.	15.5	124
126	Advanced glycation end-products induce endoplasmic reticulum stress in human aortic endothelial cells. Clinical Chemistry and Laboratory Medicine, 2014, 52, 151-60.	2.3	69

#	Article	IF	CITATIONS
127	ATP Synthesis Revisited: New Avenues for the Management of Mitochondrial Diseases. Current Pharmaceutical Design, 2014, 20, 4570-4579.	1.9	23
128	Investigation of the role of polycystin-1 and polycystin-2 in colorectal cancer Journal of Clinical Oncology, 2014, 32, e14592-e14592.	1.6	0
129	Deregulated Chromatin Remodeling in the Pathobiology of Brain Tumors. NeuroMolecular Medicine, 2013, 15, 1-24.	3.4	19
130	Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. Journal of Neural Transmission, 2013, 120, 1709-1715.	2.8	30
131	Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring. Fertility and Sterility, 2013, 99, 943-950.	1.0	34
132	Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival. British Journal of Cancer, 2013, 108, 2142-2152.	6.4	20
133	Mechanical stimulation of polycystin-1 induces human osteoblastic gene expression via potentiation of the calcineurin/NFAT signaling axis. Cellular and Molecular Life Sciences, 2013, 70, 167-180.	5.4	46
134	Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. Journal of Endocrinology, 2013, 218, 331-337.	2.6	42
135	Impact of 5-HTTLPR Polymorphism on Alexithymia in Alcoholic Patients After Detoxification Treatment. Journal of Addiction Medicine, 2013, 7, 372-373.	2.6	4
136	Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines. Current Alzheimer Research, 2013, 10, 154-164.	1.4	12
137	The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas. Neurology Research International, 2012, 2012, 1-13.	1.3	3
138	Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis. Current Alzheimer Research, 2012, 9, 491-499.	1.4	13
139	Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. International Journal of Biochemistry and Cell Biology, 2012, 44, 1276-1289.	2.8	41
140	Crosstalk between Advanced Glycation and Endoplasmic Reticulum Stress: Emerging Therapeutic Targeting for Metabolic Diseases. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2231-2242.	3.6	146
141	Reduced Ovarian Glyoxalase-I Activity by Dietary Glycotoxins and Androgen Excess: A Causative Link to Polycystic Ovarian Syndrome. Molecular Medicine, 2012, 18, 1183-1189.	4.4	43
142	Expression of Interleukin-8 Receptor CXCR2 and Suppressor of Cytokine Signaling-3 in Astrocytic Tumors. Molecular Medicine, 2012, 18, 379-388.	4.4	15
143	Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opinion on Investigational Drugs, 2012, 21, 1475-1488.	4.1	75
144	Phosphorylated 4Eâ€binding protein 1 (pâ€4Eâ€BP1): a novel prognostic marker in human astrocytomas. Histopathology, 2012, 61, 293-305.	2.9	46

#	Article	IF	Citations
145	Molecular Mechanisms Regulating Matrix Metalloproteinases. Current Topics in Medicinal Chemistry, 2012, 12, 1095-1112.	2.1	46
146	Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: Correlation with IL-6, VEGF and microvessel morphometry. Cytokine, 2011, 55, 387-395.	3.2	45
147	Early shear stress signaling on vascular endothelium by a modified partial carotid ligation model. International Journal of Cardiology, 2011, 152, 413-416.	1.7	3
148	Strong and positive association of Endothelin-1 with AGEs in PCOS: A causal relationship or a bystander?. Hormones, 2011, 10, 292-297.	1.9	30
149	Strategies for DNA methylation analysis in developmental studies. Development Growth and Differentiation, 2011, 53, 287-299.	1.5	4
150	Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. Journal of Bone and Mineral Metabolism, 2011, 29, 201-206.	2.7	30
151	Androgens associated with advanced glycation end-products in postmenopausal women. Menopause, 2010, 17, 1182-1187.	2.0	30
152	Vitamin B12 Levels in Alzheimer's Disease: Association with Clinical Features and Cytokine Production. Journal of Alzheimer's Disease, 2010, 19, 481-488.	2.6	39
153	Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. Journal of Cellular and Molecular Medicine, 2010, 14, 2460-2469.	3.6	57
154	APOE epsilonâ€4 allele and cytokine production in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 338-344.	2.7	33
155	High Incidence of MGMT and RAR \hat{I}^2 Promoter Methylation in Primary Glioblastomas: Association with Histopathological Characteristics, Inflammatory Mediators and Clinical Outcome. Molecular Medicine, 2010, 16, 1-9.	4.4	48
156	Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 Variations Does Not Impact Alcohol Dependence Disorder Features. International Journal of Environmental Research and Public Health, 2009, 6, 1980-1990.	2.6	10
157	Functional alterations in mechanical loading of condylar cartilage induces changes in the bony subcondylar region. Archives of Oral Biology, 2009, 54, 1035-1045.	1.8	22
158	TPH2 gene variants and anxiety during alcohol detoxification outcome. Psychiatry Research, 2009, 167, 106-114.	3.3	10
159	Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Human Immunology, 2009, 70, 391-397.	2.4	47
160	Hyperreninemia Characterizing Women with Polycystic Ovary Syndrome Improves after Metformin Therapy. Kidney and Blood Pressure Research, 2009, 32, 24-31.	2.0	18
161	Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. European Journal of Endocrinology, 2009, 160, 847-853.	3.7	62
162	Lack of Association between Interleukin-1 alpha rs1800587 Polymorphism and Alzheimer's Disease in Two Independent European Samples. Journal of Alzheimer's Disease, 2009, 16, 181-187.	2.6	24

#	Article	IF	CITATIONS
163	Cytokine Secretion in Long-standing Diabetes Mellitus Type 1 and 2: Associations with Low-grade Systemic Inflammation. Journal of Clinical Immunology, 2008, 28, 314-321.	3.8	113
164	Increased serum advanced glycation endâ€products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2008, 69, 634-641.	2.4	162
165	Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. Journal of Cellular and Molecular Medicine, 2008, 12, 1495-1501.	3.6	23
166	The knowledge of osteoporosis risk factors in a Greek female population. Maturitas, 2008, 59, 38-45.	2.4	33
167	Increased plasma levels of 8-iso-PGF2α and IL-6 in an elderly population with depression. Psychiatry Research, 2008, 161, 59-66.	3.3	105
168	DNA methylation signature analysis: how easy is it to perform?. Journal of Biomolecular Techniques, 2008, 19, 281-4.	1.5	7
169	Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. British Journal of Cancer, 2007, 97, 1124-1134.	6.4	54
170	Characterization of the Lipid Profile in Dementia and Depression in the Elderly. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 138-144.	2.3	35
171	Depression and Social Phobia Secondary to Alcohol Dependence. Neuropsychobiology, 2007, 56, 111-118.	1.9	7
172	Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine, 2007, 39, 99-105.	3.2	62
173	Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2007, 56, 129-134.	3.4	67
174	Correlation of folate, vitamin B12 and homocysteine plasma levels with depression in an elderly Greek population. Clinical Biochemistry, 2007, 40, 604-608.	1.9	51
175	Accumulation of dietary glycotoxins in the reproductive system of normal female rats. Journal of Molecular Medicine, 2007, 85, 1413-1420.	3.9	84
176	Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Molecular and Cellular Biochemistry, 2007, 295, 75-83.	3.1	31
177	Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Molecular and Cellular Biochemistry, 2007, 304, 343-351.	3.1	65
178	Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochemistry and Cell Biology, 2007, 127, 581-589.	1.7	151
179	Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clinical Biochemistry, 2007, 40, 336-342.	1.9	50
180	Vitamin B12 and hepatic enzyme serum levels correlate with interleukin-6 in alcohol-dependent individuals without liver disease. Clinical Biochemistry, 2007, 40, 781-786.	1.9	6

#	Article	IF	Citations
181	Correlation of liver dysfunction biological markers to the mood status of alcohol-dependent individuals. International Journal of Psychiatry in Clinical Practice, 2006, 10, 166-173.	2.4	0
182	Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2006, 55, 494-500.	3.4	33
183	Indices of low-grade chronic inflammation correlate with early cognitive deterioration in an elderly Greek population. Neuroscience Letters, 2006, 398, 118-123.	2.1	43
184	Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome. Neuroscience Letters, 2006, 406, 107-112.	2.1	10
185	Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology, 2006, 66, 061031010617005-???.	2.4	47
186	Inflammatory and endothelial markers in women with polycystic ovary syndrome. European Journal of Clinical Investigation, 2006, 36, 691-697.	3.4	141
187	Differences in Expression of Cardiovascular Risk Factors among Type 2 Diabetes Mellitus Patients of Different Age. Annals of the New York Academy of Sciences, 2006, 1084, 166-177.	3.8	16
188	Inflammatory Process in Type 2 Diabetes: The Role of Cytokines. Annals of the New York Academy of Sciences, 2006, 1084, 89-117.	3.8	255
189	Elevation of plasma concentration of adhesion molecules in lateâ€life depression. International Journal of Geriatric Psychiatry, 2006, 21, 965-971.	2.7	49
190	Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reproduction, 2006, 21, 1426-1431.	0.9	225
191	Polycystic Ovary Syndrome: The influence of environmental and genetic factors. Hormones, 2006, 5, 17-34.	1.9	104
192	Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones, 2006, 5, 126-136.	1.9	34
193	Interrelationship of hepatic function, thyroid activity and mood status in alcohol-dependent individuals. In Vivo, 2006, 20, 293-300.	1.3	13
194	Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology, 2005, 62, 37-43.	2.4	151
195	Evidence of reduced plasma HDL subfractions in patients with cutaneous discoid lupus erythematosus. Clinical Biochemistry, 2005, 38, 286-290.	1.9	9
196	Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Molecular and Cellular Biochemistry, 2005, 268, 19-24.	3.1	65
197	Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Human Reproduction Update, 2005, 11, 631-643.	10.8	133
198	Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology, 2005, 152, 749-756.	3.7	161

#	Article	lF	CITATIONS
199	Effects of hormone replacement therapy on the main fatty acids of serum and phospholipids of postmenopausal women. In Vivo, 2005, 19, 1081-5.	1.3	2
200	Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women. Molecular and Cellular Biochemistry, 2004, 261, 71-75.	3.1	4
201	Tumour–stroma interactions in carcinogenesis: Basic aspects and perspectives. Molecular and Cellular Biochemistry, 2004, 261, 117-122.	3.1	37
202	Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients. Molecular and Cellular Biochemistry, 2004, 265, 57-61.	3.1	29
203	The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease. Clinical Biochemistry, 2004, 37, 377-381.	1.9	22
204	Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women. Journal of Obstetrics and Gynaecology, 2004, 24, 414-419.	0.9	5
205	Altered long chain fatty acids composition in Duchenne muscular dystrophy erythrocytes. In Vivo, 2004, 18, 799-802.	1.3	8
206	The cytotoxic effect of volatile organic compounds of the gas phase of cigarette smoke on lung epithelial cells. Free Radical Biology and Medicine, 2003, 34, 345-355.	2.9	63
207	Comparison of CD22 binding to native CD45 and synthetic oligosaccharide. European Journal of Immunology, 2002, 32, 1924.	2.9	57
208	Design and synthesis of a multivalent homing device for targeting to murine CD22. Bioorganic and Medicinal Chemistry, 2001, 9, 85-97.	3.0	15
209	A Structure-Function Study of Ligand Recognition by CD22β. Journal of Biological Chemistry, 2001, 276, 12967-12973.	3.4	17